AURA
Aura Biosciences, Inc. [AURA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
AURA Stock Summary
In the News
AURA Financial details
Company Rating
-
Market Cap
373.26M
Income
-74.1M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
88
Optionable
No
Shortable
Yes
Earnings
06 May 2024
P/E
-3.64
Forward P/E
-
PEG
13.9
P/S
-
P/B
2.25
P/C
-
P/FCF
-6.75
Quick Ratio
13.68
Current Ratio
14.13
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.86
EPS next Y
-
EPS next Q
-
EPS this Y
1.05%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
4.17%
-
-
-
-
SMA20
-
SMA50
-14.29%
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-52%
ROE
-54%
ROC
-0.45%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
5.99-13.5
52W High
-53.35%
52W Low
+21.3%
RSI
51
Rel Volume
1.14
Avg Volume
185.42K
Volume
210.51K
Perf Week
-0.9%
Perf Month
-3.12%
Perf Quarter
15.97%
Perf Half Y
10.07%
-
-
-
-
Beta
0.352
-
-
Volatility
0.26%, 0.18%
Prev Close
-4.79%
Price
6.065
Change
-0.57%
Company Profile
- Volume Average 185.42K
- Market Capitalization 373.26M
- Employee 88
- CEO Dr. Elisabet de los Pinos Ph.D.
- Headquarters Cambridge,MA,US
- IPO Date 2021-10-29
-
Website
https://www.aurabiosciences.com 
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
